Is NCT05442515 recruiting in Bethesda, MD?

Yes, NCT05442515 is currently recruiting participants at its Bethesda, MD location. This b-nhl clinical trial is actively enrolling qualified participants.

How do I join the b-nhl clinical trial in Bethesda?

To join this clinical trial in Bethesda, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bethesda clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

B-NHL Clinical Trial in Bethesda, MD

About This B-NHL Study in Bethesda

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL. Eligibility: People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy. Design: Participants will be screened. This will include: Physical exam Blood and urine tests Tests of their lung and heart function Imaging scans Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone. Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord. Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells. Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment. Participants will be admitted to the hospital. Their own modified T cells will be returned to their body. Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Participant must:

Have pathology confirmed B cell ALL (not isolated to the testis or CNS), CML with ALL transformation, or high-grade lymphoma (e.g., Burkitt's lymphoma, B-lymphoblastic lymphoma, diffuse large B-cell lymphoma, inclusive of low-grade lymphoma that has transformed to high grade disease); and

Have relapsed or been refractory after at least one standard chemotherapy regimen and at least one salvage treatment. Participants with Philadelphia chromosome + ALL must have failed prior tyrosine kinase inhibitor; and

Be ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have recurred after SCT; and

Be unable to access (in a timely manner), ineligible for, or have relapsed/failed after or not responded to a commercially available CD19 CAR T-cell construct; and

Have evidence of at least minimal residual disease or PET-avid disease (lymphoma) at the time of enrollment.

CD22/CD19 expression

Cohorts A1b, B1b, C2b

CD19 must be detected on \>15% of the malignant cells by immunohistochemistry or \> 80% by flow cytometry.

CD22 positivity must be confirmed.

Cohorts D1b, 2 B-ALL

CD19 or CD22 positivity must be confirmed

Age \>= 3 years of age and \<=39 years of age at time of enrollment.

Clinical Performance status: Participants \>= 16 years of age: Karnofsky \>= 50%; Participants \< 16 years of age: Lansky scale \>= 50%.

Participants must have adequate organ and marrow function as defined below:

leukocytes \>= 750/mcL\

platelets \>= 50,000/mcL\

total bilirubin \<=2 X ULN (except in the case of participants with documented Gilbert's disease \> 3x ULN)

AST(SGOT)/ALT(SGPT) \<=10 X institutional upper limit of normal

creatinine \<= the maximum for age listed in the table below OR

measured creatinine clearance \>=60 mL/min/1.73 m\^2 for participants with creatinine levels above the max listed below per age.

Age (Years) \<= 5 / Maximum Serum Creatinine (mg/dL) \<= 0.8

Age (Years) 6 to \<= 10 / Maximum Serum Creatinine (mg/dL) \<= 1.0

Age (Years) \>10 / Maximum Serum Creatinine (mg/dL) \<= 1.2

a participant will not be excluded because of pancytopenia \>= Grade 3 if it is due to underlying bone marrow involvement by leukemia

Central nervous system (CNS) Status

Participants with leukemia with CNS 1 and 2 disease are eligible in the absence of

Exclusion Criteria

Participants of child-bearing or child-fathering potential must be willing to practice effective birth control from the time of enrollment until 12 months following completion of study treatment for women and for 4 months following completion of study treatment for men.

Participants who are breastfeeding or plan to breastfeed must agree to discontinue/postpone breastfeeding while on study therapy and until 1 month after the administration of CAR.

Cardiac function: Left ventricular ejection fraction \>= 45% or fractional shortening \>=28%

Pulmonary Function

Baseline oxygen saturation \>92% on room air at rest

Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.

Ability and willingness of participant or Legally Authorized Representative (LAR) to co- enroll on 15-C-0028: Follow-up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials. EXCLUSION CRITERIA: Participants meeting any of the following criteria are not eligible for participation in the study:

Participants with CNS3 disease, progressing neurologic signs\

of CNS disease, radiologically detected active CNS lymphoma (\*resolving manifestation or persistent and/or irreversible findings from prior CNS involvement (e.g., blindness) is not exclusionary)

Hyperleukocytosis (\>= 50,000 blasts/microL)

Positive serum or urine beta-HCG pregnancy test performed at screening.

Participants will be excluded based on prior therapy if they fail to meet following washout criteria:

Therapy: Systemic Chemotherapy, anti-neoplastic agents, antibody- based therapies

Washout\*: \>=2 weeks

Exceptions: 6 weeks for clofarabine or nitrosoureas; No washout for prior intrathecal chemotherapy, steroid therapy, hydroxyurea (no dose increases within prior 2 weeks) or ALL maintenance-type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for participants with Ph+ ALL) provided there is recovery from any acute toxic effects

Therapy: Radiation

Washout\*: \>=3 weeks

Exceptions: No time restriction with radiation therapy if the volume of bone marrow treated is less than 10% and the participant has measurable/evaluable disease outside the radiation window

Therapy: Allogeneic Stem Cell Transplant

Washout\*: \>= 100 days since SCT; \>= 30 days since completion of immunosuppression; \>= 6 weeks since donor lymphocyte infusion (DLI)

Exceptions: Cannot have evidence of active graft-versus-host disease (GVHD) requiring systemic immunosuppression

Therapy: CAR T-Cell Therapy or other Adoptive Cell Therapy

Washout\*: \> 30 days post infusion

Washout: Time between therapy and apheresis

Positive HIV antibodies consistent with active HIV.

Positive hepatitis C antibodies or positive Hepatitis B surface antigen (HbsAG) indicative of current/active HCV/HBV.

Active second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and participant is in remission.

History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells.

Uncontrolled, symptomatic, intercurrent illness or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the participant.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT05442515) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-NHL Treatment Options in Bethesda, MD

If you're searching for b-nhl treatment options in Bethesda, MD, this clinical trial (NCT05442515) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced b-nhl specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all b-nhl clinical trials near you to find additional studies recruiting in your area.

B-NHL Clinical Trial in Bethesda, MD

Expert Care in Bethesda

IRB Approved

No-Cost Care

Apply for This Bethesda Location

Why Participate?

Simple Process